-- 日本物流基金（東京證券交易所代號：8967）的資產管理人三井物產物流夥伴公司決定修改該房地產投資信託基金（REIT）的資產管理指引，自4月23日起生效。 此修改旨在透過在其房地產相關資產之外新增資產類別，擴大REIT的投資機會，這些新資產類別包括主要投資於房地產類資產的投資企業的有限合夥權益以及貨幣債權。 相應地，修訂後的指引將更新REIT的投資組合建構政策，並引入新的條款，用於確認與收購這些新增資產類別相關的事項。 根據週一提交給東京證券交易所的文件，此修改須經股東在當日舉行的第16屆股東大會上批准，並對公司章程進行部分修訂。
Related Articles
Australia
BofA Adjusts Price Target on Pool to $226 From $229
Pool (POOL) has an average rating of overweight and mean price target of $262.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $228.70, Change: $+1.08, Percent Change: +0.47%
$POOL
Australia
BofA Adjusts Price Target on SiteOne Landscape Supply to $167 From $182
SiteOne Landscape Supply (SITE) has an average rating of overweight and mean price target of $169.09, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $142.26, Change: $-2.10, Percent Change: -1.45%
$SITE
Australia
Arcus Biosciences Discontinues Phase 3 Lung Cancer Trial for Futility
Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%
$GILD$RCUS